Integrated Filing — IndAS



General information about company

Scrip Code 532851
NSE Symbol INSECTICID
MSEI Symbol NA
ISIN INE070I01018
Name of company Insecticides (India) Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 28-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 16-04-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Agro-chemicals
Start date and time of board meeting 28-05-2026   13:00:00
End date and time of board meeting 28-05-2026   16:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 10-02-2025
Indicate Company website link for updated RPT policy of the Company https://insecticidesindia.com/wp-content/uploads/2025/05/Revised-Related-Party-Transaction-Policy-10022025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NIL



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 42,795.60 2,14,414.11
Other income 480.29 1,211.12
Total income 43,275.89 2,15,625.23
2 Expenses
(a) Cost of materials consumed 26,829.00 1,24,564.76
(b) Purchases of stock-in-trade 3,139.60 13,290.04
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 110.06 10,375.48
(d) Employee benefit expense 3,641.99 15,984.90
(e) Finance costs 418.05 1,651.20
(f) Depreciation, depletion and amortisation expense 932.43 3,521.60
(f) Other Expenses
1 Other expenses 6,334.52 28,039.55
Total other expenses 6,334.52 28,039.55
Total expenses 41,405.65 1,97,427.53
3 Total profit before exceptional items and tax 1,870.24 18,197.70
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,870.24 18,197.70
6 Tax expense
7 Current tax 76.56 4,224.13
8 Deferred tax 357.31 391.83
9 Total tax expenses 433.87 4,615.96
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,436.37 13,581.74
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,436.37 13,581.74
17 Other comprehensive income net of taxes 239.45 221.56
18 Total Comprehensive Income for the period 1,675.82 13,803.30
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,909.78 2,909.78
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 1,18,490.59
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.94 46.68
Diluted earnings (loss) per share from continuing operations 4.94 46.68
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.94 46.68
Diluted earnings (loss) per share from continuing and discontinued operations 4.94 46.68
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1 The above Audited Standalone Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 as amended. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 28 2026. The auditors of the company have carried out the audit of the same. The Audit Report along with Financial Results for the quarter and year ended March 31 2026 are available on the Stock Exchanges website at www.bseindia.com www.nseindia.com and on the Companys website www.insecticidesindia.com 2. The above Audited Standalone Financial Results have been prepared in accordance with the Indian Accounting Standard Ind AS the provisions of the Companies Act 2013 the Act as applicable and guidelines issued by the Securities and Exchange Board of India SEBI. The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies Indian Accounting Standards Rules 2015 and subsequent amendments thereto. 3. The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz Agro-Chemicals comprising of Technical and Formulation. 4. The Board of Directors of Insecticides India Limited in its meeting held on August 09 2024 had approved the dissolution/ liquidation of its wholly owned subsidary IIL Overseas DMCC Dubai. IIL Overseas DMCC has filled the windupdissolution with DMCCA Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority and dissolution is approved vide its letter dated September 19 2025. 5. The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019 Code on Social Security 2020 Industrial Relation Code 2020 and Occupational Safety Health and Working Condition Code 2020 collectively referred to as the New Labour Codes These Codes have been made effective from November 21 2025. The corresponding all supporting rules under these codes are yet to be notified. The Company has estimated that there is no incremental liability due to implications of these laws to the standalone financial statements. Further the Company continues to monitor the finalisation of CentralState Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 6. The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year up to 31 March 2026 and the unaudited published year-to-date figures up to 31 December 2025 being the date of the end of the third quarter of the financial year which were subjected to a limited review.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 30,928.77
Capital work-in-progress 11,844.88
Investment property 99.87
Goodwill 0.00
Other intangible assets 793.81
Intangible assets under development 1,108.48
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 1,819.27
Non-current financial assets
Non-current investments 1,230.16
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other non-current financial assets 429.23
Total of other non-current financial assets 429.23
Total non-current financial assets 1,659.39
Deferred tax assets (net) 477.40
Other non-current assets
1 Other non-current assets 6,575.54
Total of other non-current assets 6,575.54
Total non-current assets 55,307.41
2 Current assets
Inventories 76,831.32
Current financial asset
Current investments 0.00
Trade receivables, current 48,949.61
Cash and cash equivalents 8,712.51
Bank balance other than cash and cash equivalents 16.77
Loans, current 26.87
Other current financial assets
Total of other current financial assets 1,318.15
Total current financial assets 59,023.91
Current tax assets (net) 0.00
Other current assets
1 Other current assets 7,379.82
Total of other current assets 7,379.82
Total current assets 1,43,235.05
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,98,542.46
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,909.78
Other equity 1,18,490.59
Total equity attributable to owners of parent 1,21,400.37
Non controlling interest
Total equity 1,21,400.37
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,798.34
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 887.82
Total of other non-current financial liabilities 887.82
Total non-current financial liabilities 2,686.16
Provisions, non-current 288.59
Deferred tax liabilities (net) 942.78
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 3,917.53
Current liabilities
Current financial liabilities
Borrowings, current 12,092.38
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 6,918.58
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 37,075.43
Total Trade payable 43,994.01
Other current financial liabilities
1 Lease Liabilities and other financial liabilities 4,703.97
Total of other current financial liabilities 4,703.97
Total current financial liabilities 60,790.36
Other current liabilities 12,016.05
1 Other current liabilities 12,016.05
Total of other current liabilities 12,016.05
Provisions, current 418.15
Current tax liabilities (Net) 0.00
Deferred government grants, Current
Total current liabilities 73,224.56
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 77,142.09
Total equity and liabilites 1,98,542.46
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Changes in fair value of FVTOCI equity instruments 328.87 407.98
2 Remeasurement of net defined benefit plans (17.11) (122.11)
3 Income tax relating to these items (72.31) (64.31)
Total Amount of items that will not be reclassified to profit and loss 239.45 221.56
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 239.45 221.56



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 18,197.70
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,651.20
Adjustments for decrease (increase) in inventories 11,436.69
Adjustments for decrease (increase) in trade receivables, current (10,342.99)
Adjustments for decrease (increase) in trade receivables, non-current (1.86)
Adjustments for decrease (increase) in other current assets 431.26
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (49.68)
Adjustments for other financial assets, current 174.09
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (6,667.91)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (1,039.85)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 3,521.60
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (443.56)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (369.74)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 26.00
Adjustments for interest income 26.08
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (123.59)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,876.42)
Net cash flows from (used in) operations 16,321.28
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 5,448.87
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 10,872.41
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses (4.29)
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 203.46
Purchase of property, plant and equipment 9,274.38
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 10.89
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 34.42
Interest received 26.08
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (9,017.02)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 5,138.71
Repayments of borrowings 1,319.09
Payments of lease liabilities 271.78
Dividends paid 581.96
Interest paid 1,646.77
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 1,319.11
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 3,174.50
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 3,174.50
Cash and cash equivalents cash flow statement at beginning of period 5,538.01
Cash and cash equivalents cash flow statement at end of period 8,712.51





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S S Kothari Mehta & Co., LLP Yes 31-08-2028
2 Devesh Parekh & Co Yes 29-02-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Insecticides (India) Limited Hari Chand Aggarwal Chairman / KMP Remuneration 0.00 No adverse Remark 285.88 14.20 11.30
2 Insecticides (India) Limited Rajesh Kumar Aggarwal Managing Director / KMP Remuneration 0.00 No adverse Remark 288.40 13.94 11.49
3 Insecticides (India) Limited Nikunj Aggarwal Whole-time Director / KMP Remuneration 0.00 No adverse Remark 25.60 6.26 5.06
4 Insecticides (India) Limited Anil Kumar Goyal Whole-time Director / KMP Remuneration 0.00 No adverse Remark 7.69 3.26 1.50
5 Insecticides (India) Limited Sandeep Aggarwal Chief Financial Officer / KMP Remuneration 0.00 No adverse Remark 33.76 6.15 5.04
6 Insecticides (India) Limited Sandeep Kumar Company Secreatary / KMP Remuneration 0.00 No adverse Remark 19.73 4.09 4.18
7 Insecticides (India) Limited Sanskar Aggarwal Relative of KMP Remuneration 0.00 No adverse Remark 14.38 3.66 2.99
8 Insecticides (India) Limited Sanjeev Aggarwal Relative of KMP Remuneration 0.00 No adverse Remark 24.56 3.83 3.86
9 Insecticides (India) Limited Praveen Gupta Independent Director Any other transaction sitting fees 0.00 No adverse Remark 3.75 0.00 0.00
10 Insecticides (India) Limited Anil Kumar Bhatia Independent Director Any other transaction sitting fees 0.00 No adverse Remark 4.10 0.00 0.00
11 Insecticides (India) Limited Shyam Lal Bansal Independent Director Any other transaction sitting fees 0.00 No adverse Remark 4.45 0.00 0.00
12 Insecticides (India) Limited Supratim Bandyopadhyay Independent Director Any other transaction sitting fees 0.00 No adverse Remark 3.75 0.00 0.00
13 Insecticides (India) Limited Sonia Aggarwal Relative of KMP Any other transaction consultancy fees 30.00 No adverse Remark 6.46 0.84 0.84
14 Insecticides (India) Limited Anju Aggarwal Relative of KMP Remuneration 0.00 No adverse Remark 9.00 2.80 2.37
15 Insecticides (India) Limited Pushpa Aggarwal Relative of KMP Any other transaction Rent paid 69.00 No adverse Remark 5.82 0.00 0.00
16 Insecticides (India) Limited ISEC Organics Limited Directors and Directors relatives holding more than 2% Any other transaction Rent paid 1,000.00 No adverse Remark 3.08 0.00 0.00
17 Insecticides (India) Limited ISEC Organics Limited Directors and Directors relatives holding more than 2% Any other transaction Rent (Including lease rent) 1,000.00 No adverse Remark 88.50 0.00 0.00
18 Insecticides (India) Limited ISEC Organics Limited Directors and Directors relatives holding more than 2% Any other transaction Advance Received back 1,000.00 No adverse Remark 0.00 203.26 203.26
19 Insecticides (India) Limited IIL Foundation Trust in which Promoter is a Trustee Any other transaction Corporate Social Responsibility 281.00 No adverse Remark 140.50 0.00 0.00
20 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Purchase of goods or services 2,000.00 No adverse Remark 234.37 119.54 84.26
21 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Any other transaction Rental Income 2,000.00 No adverse Remark 6.76 0.00 0.00
22 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Sale of goods or services 2,000.00 No adverse Remark 116.50 25.75 39.99
23 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Any other transaction Security Deposit Received 2,000.00 No adverse Remark 2.63 0.00 2.63
24 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Any other transaction Reimbursement of expenses 2,000.00 No adverse Remark 0.97 0.00 0.00
25 Insecticides (India) Limited Kaeros Research Ltd. formerly known as Kaeros Research P Ltd. Wholly-owned Subsidiary Purchase of goods or services 20,000.00 No adverse Remark 5,136.20 2,856.86 2,534.24
26 Insecticides (India) Limited Kaeros Research Ltd. formerly known as Kaeros Research P Ltd. Wholly-owned Subsidiary Any other transaction Rental Income 20,000.00 No adverse Remark 23.87 0.00 0.00
27 Insecticides (India) Limited Kaeros Research Ltd. formerly known as Kaeros Research P Ltd. Wholly-owned Subsidiary Sale of goods or services 20,000.00 No adverse Remark 581.01 1,458.35 367.09
28 Insecticides (India) Limited Kaeros Research Ltd. formerly known as Kaeros Research P Ltd. Wholly-owned Subsidiary Any other transaction Expenses Reimbursement 20,000.00 No adverse Remark (0.66) 0.00 0.00
29 Insecticides (India) Limited Kaeros Research Ltd. formerly known as Kaeros Research P Ltd. Wholly-owned Subsidiary Any other transaction Security deposit received against rent 20,000.00 No adverse Remark 9.74 0.00 9.74
30 Insecticides (India) Limited Valve & Pneumatics Directors Relatives holding more than 2% Purchase of goods or services 600.00 No adverse Remark 0.00 0.00 0.00
31 Insecticides (India) Limited Valve & Pneumatics Directors Relatives holding more than 2% Sale of goods or services 600.00 No adverse Remark 0.00 0.00 0.00
32 Insecticides (India) Limited OAT & IIL India Laboratories Private Limited Joint Venture (Enterprises over which the Company exercises joint control) Any other transaction Deputation fee income 1,720.00 No adverse Remark 24.19 0.00 0.00
33 Insecticides (India) Limited OAT & IIL India Laboratories Private Limited Joint Venture (Enterprises over which the Company exercises joint control) Any other transaction Job Work Income / Revenue from manpower supply 1,720.00 No adverse Remark 12.46 14.16 8.91
34 Insecticides (India) Limited OAT & IIL India Laboratories Private Limited Joint Venture (Enterprises over which the Company exercises joint control) Purchase of goods or services 1,720.00 No adverse Remark 244.02 0.00 0.00
35 Insecticides (India) Limited Vinod Metal Industries Directors Relatives holding more than 2% Purchase of goods or services 600.00 No adverse Remark 125.45 17.39 91.88
36 Insecticides (India) Limited Indogulf Cropsciences Ltd. Directors Relatives holding more than 2% Purchase of goods or services 1,500.00 No adverse Remark 55.46 0.00 0.00
37 Insecticides (India) Limited Indogulf Cropsciences Ltd. Directors Relatives holding more than 2% Sale of goods or services 1,500.00 No adverse Remark 137.18 36.60 81.73
38 Insecticides (India) Limited Crystal Crop Protection Ltd. Directors Relatives holding more than 2% Purchase of goods or services 5,000.00 No adverse Remark 53.10 0.00 0.00
39 Insecticides (India) Limited Crystal Crop Protection Ltd. Directors Relatives holding more than 2% Sale of goods or services 5,000.00 No adverse Remark 955.69 668.71 942.45
40 Insecticides (India) Limited HPM Chemicals and Fertilizers Ltd. Directors Relatives holding more than 2% Purchase of goods or services 2,500.00 No adverse Remark 885.00 0.22 208.98
41 Insecticides (India) Limited HPM Chemicals and Fertilizers Ltd. Directors Relatives holding more than 2% Sale of goods or services 2,500.00 No adverse Remark 209.10 2.09 884.25
42 Insecticides (India) Limited Crop Care Federation of India KMP is the Director Any other transaction Subscription fees 50.00 No adverse Remark 11.80 0.00 0.00
43 Insecticides (India) Limited Crop Care Federation of India KMP is the Director Any other transaction Contribution Towards Legal Exp 50.00 No adverse Remark 8.85 0.00 0.00
44 Insecticides (India) Limited Crop Care Federation of India KMP is the Director Any other transaction Adv Exp 50.00 No adverse Remark 0.24 0.00 0.00
Total value of transaction during the reporting period 9,803.34